Cheryl Gault's most recent trade in Rapport Therapeutics Inc. was a trade of 3,792 Common Stock done at an average price of $41.4 . Disclosure was reported to the exchange on June 30, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 41.39 per share. | 30 Jun 2026 | 3,792 | 154,222 | - | 41.4 | 156,964 | Common Stock |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 42.17 per share. | 30 Jun 2026 | 3,308 | 150,914 | - | 42.2 | 139,506 | Common Stock |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 40.09 per share. | 30 Jun 2026 | 1,900 | 158,014 | - | 40.1 | 76,174 | Common Stock |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 43.16 per share. | 30 Jun 2026 | 1,000 | 149,914 | - | 43.2 | 43,155 | Common Stock |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 28.04 per share. | 30 Mar 2026 | 7,161 | 162,753 | - | 28.0 | 200,795 | Common Stock |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 28.55 per share. | 30 Mar 2026 | 2,839 | 159,914 | - | 28.6 | 81,062 | Common Stock |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 28.93 per share. | 05 Mar 2026 | 2,014 | 169,914 | - | 28.9 | 58,265 | Common Stock |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 132,000 | 132,000 | - | - | Stock Option (Right to Buy) | |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.80 per share. | 26 Nov 2025 | 5,000 | 176,928 | - | 1.8 | 9,000 | Common Stock |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2025 | 5,000 | 105,407 | - | - | Stock Option (Right to Buy) | |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 30.10 per share. | 26 Nov 2025 | 5,000 | 171,928 | - | 30.1 | 150,487 | Common Stock |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2025 | 5,000 | 110,407 | - | - | Stock Option (Right to Buy) | |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 38.33 per share. | 08 Sep 2025 | 5,000 | 171,928 | - | 38.3 | 191,650 | Common Stock |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.80 per share. | 08 Sep 2025 | 5,000 | 176,928 | - | 1.8 | 9,000 | Common Stock |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 13,987 | 171,928 | - | 0 | Common Stock | |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 129,000 | 129,000 | - | - | Stock Option (Right to Buy) | |
| Rapport Therapeutics Inc | Cheryl Gault | Chief Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 88,442 | 88,442 | - | - | Stock Option (Right to Buy) | |
| Cyclerion Therapeutics Inc | Cheryl Gault | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2022 | 135,000 | 135,000 | - | - | Employee Stock Option (Right to Buy) |